Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone Added to Metformin + Empagliflozin in Type 2 Diabetes
2023-508924-36-00Phase 3Completed
- Sponsor
- Celltrion
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Pioglitazone add-on with Placebo add-on (2 arms). Primary endpoint: Change from baseline in HbA1c at Week 24 of the treatment. Started May 2024; status: completed.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2023-508924-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508924-36-00.